# Dynacure

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/dynacure

- Industry: Biotechnology
- Headquarters: Illkirch-Graffenstaden, France
- Website: www.dynacure.com
- Total disclosed funding: $102M
- Latest round: Series C (Apr 2, 2020)
- Investors on record: 9

## About

Based in Illkirch-Graffenstaden, France and founded in 2016, Dynacure SA operates as a biotechnology company that develops therapeutic drugs for the treatment of Myotubular and Centronuclear Myopathies (CNM). The company has 25 employees as of June 30, 2021 and was founded by its CEO, Stéphane van Rooijen, alongside Dr. Belinda Cowling. In April 2020, the company received its latest series C funding from a group of investors that included Andera Partners, Bpifrance, and Kurma Partners.

The company's product is a therapeutic solution that provides treatment for neuromuscular diseases, including myotubular and centronuclear myopathies or CNM, and other rare diseases. It develops DYN101, an antisense oligonucleotide, or ASO, that serves as a modifying medicine for the treatment of the majority of CNM patients. It reduces the expression of dynamin 2 or DNM2, a protein in the body that an excessive amount might affect the muscle cells of the human system. The company also offers DYN201, a discovery stage program that develops a potential treatment for a group of rare inherited neurodegenerative disorders called hereditary spastic paraplegias or HSP.

The company's revenue is generated by the sales of its therapeutic solutions DYN101 and DYN201 to patients suffering from Myotubular and Centronuclear Myopathies (CNM) and hereditary spastic paraplegias or HSP.

Dynacure SA plans to conduct a Phase 1/2 trial in Europe of DYN101 and expand its trial to sites in the US in 2H21.

## Funding rounds

- Series C, Apr 2, 2020, $62M — Andera Partners, Eurazeo, Tekla Capital Management, Pontifax Venture Capital, Kurma Partners, Sphera Fund Management, Bpifrance, Perceptive Advisors
- Series B, Feb 2, 2020, $16M — Andera Partners, Pontifax Venture Capital, Kurma Partners, Eurazeo, Bpifrance, Ionis Pharmaceuticals, Inc.
- Series B, Oct 17, 2018, $12M — Andera Partners, Pontifax Venture Capital, Kurma Partners, Eurazeo, Bpifrance
- Series A, Jan 5, 2018, $9.5M — Bpifrance, Kurma Partners, Eurazeo, Ionis Pharmaceuticals, Inc.
- Seed, Jan 31, 2017, $3.5M — Kurma Partners, Eurazeo, Ionis Pharmaceuticals, Inc.

## Investors

- Kurma Partners (https://capitalatlas.ai/funds/kurma-partners) — Seed, Series A, Series B, Series C
- Eurazeo (https://capitalatlas.ai/funds/eurazeo) — Seed, Series A, Series B, Series C
- Ionis Pharmaceuticals, Inc. — Seed, Series A, Series B
- Bpifrance — Series A, Series B, Series C
- Andera Partners (https://capitalatlas.ai/funds/andera-partners) — Series B, Series C
- Pontifax Venture Capital (https://capitalatlas.ai/funds/pontifax-venture-capital) — Series B, Series C
- Tekla Capital Management (https://capitalatlas.ai/funds/tekla-capital-management) — Series C
- Sphera Fund Management — Series C
- Perceptive Advisors (https://capitalatlas.ai/funds/perceptive-advisors) — Series C